Beyond recovery: long-term cardiovascular risks after severe COVID-19 requiring intensive care - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Long-term Cardiovascular Risks Following Severe COVID-19 Requiring Intensive Care: A Post-Recovery Perspective

  • By

  • Johanna Kämpe

  • Martin Jonson

  • Rebecka Rubenson Wahlin

  • Jacob Hollenberg

  • Per Svensson

  • Per Nordberg

  • May 25, 2026

Share

  • 1

    COVID-19 has led to over 700 million cases and 7 million deaths globally, with significant long-term cardiovascular implications.

  • 2

    Severe COVID-19 may trigger cardiovascular diseases, complicating the distinction between pre-existing conditions and infection-related effects.

  • 3

    A nationwide study assessed cardiovascular risks in ICU-treated COVID-19 patients over three years, comparing them to matched controls.

  • 4

    Primary outcomes included atherosclerotic cardiovascular disease events, while secondary outcomes focused on heart failure and atrial fibrillation.

  • 5

    Propensity score matching was used to balance comparisons between cases and controls based on demographic and clinical covariates.

Original Source(s)

Beyond recovery: long-term cardiovascular risks after severe COVID-19 requiring intensive care

  • by Johanna Kämpe, Martin Jonson, Rebecka Rubenson Wahlin, Jacob Hollenberg, Per Svensson, Per Nordberg

  • May 25, 2026

Related Content

An Indigenous Food Is Medicine Intervention: The MUTTON-HF Randomized Clinical Trial

Sanjeev Kumar Gulati, M.D., FACC, Joins Baptist Health Heart & Vascular Care

Advanced heart failure and transplant cardiologist Sanjeev Kumar Gulati, M.D., FACC, has joined Baptist Health Heart & Vascular Care, and will serve as executive deputy director and system chief of cardiovascular medicine

  • by

  • July 15, 2026

  • 3 min
Effect of Socioeconomic Status on SGLT2 Initiation in Heart Failure

A nationwide German claims analysis found lower initiation of guideline-recommended sodium-glucose cotransporter-2 inhibitors among women and patients living in lower-income municipalities.